SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-061577
Filing Date
2023-11-09
Accepted
2023-11-09 09:00:08
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evok-20231109.htm   iXBRL 8-K 48399
2 EX-99.1 evok-ex99_1.htm EX-99.1 259321
3 GRAPHIC img208171256_0.jpg GRAPHIC 7442
  Complete submission text file 0000950170-23-061577.txt   444551

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evok-20231109_pre.xml EX-101.PRE 9459
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evok-20231109.xsd EX-101.SCH 2478
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evok-20231109_lab.xml EX-101.LAB 12806
8 EXTRACTED XBRL INSTANCE DOCUMENT evok-20231109_htm.xml XML 4534
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 231390276
SIC: 2834 Pharmaceutical Preparations